Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erdafitinib in Patients With Advanced Solid Tumors With <i>FGFR</i> Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.

JCO precision oncology·2026
Same author

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026
Same author

Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

A 10-year-long ongoing complete response to vismodegib as first-line treatment in adult metastatic medulloblastoma.

Acta oncologica (Stockholm, Sweden)·2026
Same author

Clinical validation of a high-performance somatic exome sequencing assay: from target-enrichment strategy to variant calling.

NPJ genomic medicine·2026

Related Experiment Video

Updated: Jul 29, 2025

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
09:53

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

3.7K

An expanded role for surgery in grade 3 1p/19q co-deleted oligodendroglioma.

Saksham Gupta1, Noah L Nawabi1,2, Siva Emani1,3

  • 1Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Neuro-Oncology Advances
|May 22, 2023
PubMed
Summary

Repeat surgery improves survival for patients with grade 3 1p/19q co-deleted oligodendroglioma. Key survival predictors include preoperative Karnofsky Performance Status (KPS) and extent of initial tumor resection.

Keywords:
grade 3 oligodendrogliomaprogressionrecurrencerepeat surgerysurvival prediction

More Related Videos

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE
06:04

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE

Published on: August 16, 2024

908
Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy
03:13

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy

Published on: June 28, 2024

725

Related Experiment Videos

Last Updated: Jul 29, 2025

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
09:53

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

3.7K
Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE
06:04

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE

Published on: August 16, 2024

908
Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy
03:13

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy

Published on: June 28, 2024

725

Area of Science:

  • Neuro-oncology
  • Neurosurgery
  • Oncology

Background:

  • Grade 3 1p/19q co-deleted oligodendroglioma is a rare primary central nervous system (CNS) tumor.
  • This tumor type exhibits a high propensity for progression and recurrence.

Purpose of the Study:

  • To investigate the survival benefits of surgical intervention following tumor progression.
  • To identify prognostic factors influencing survival in patients with this specific oligodendroglioma subtype.

Main Methods:

  • Retrospective cohort study including adult patients diagnosed between 2001 and 2020.
  • Analysis of surgical outcomes, progression rates, overall survival (OS), and survival post-progression/recurrence.

Main Results:

  • Eighty patients were included; 53.8% experienced progression. Median OS was 14.1 years.
  • Repeat surgery in 48.8% of progressing cases correlated with improved OS (P=.041) and survival post-progression (P=.012).
  • Preoperative Karnofsky Performance Status (KPS) < 80, subtotal resection (STR)/biopsy, and postoperative deficits predicted mortality.

Conclusions:

  • Repeat surgery offers survival advantages for recurrent or progressing grade 3 1p/19q co-deleted oligodendrogliomas.
  • Initial surgical extent (gross total resection - GTR) and preoperative patient condition are critical for long-term outcomes.